Cambridge biotech Dyax Corp. reports it has granted a non-exclusive license to Dyax’s proprietary antibody phage display libraries to Kadmon Corp. LLC of New York.

While specific financial details of the deal were not released, Dyax (Nasdaq: DYAX) said in a release that the agreement includes upfront and annual license fees, clinical and regulatory milestone payments. Dyax is also entitled to royalties on net sales of any products identified using its technology that may be developed and commercialized by New York firm Kadmon.

SOURCE